培哚普利/吲达帕胺复合制剂对原发性高血压患者降压疗效及安全性观察  

The combination of Perindopril and Indapamide in treatment of essential hypertension

作　　者：刘忠[1] 姚雪艳[1] 陈君柱[1] 朱建华[1] 章黎苹[1] 金争鸣[1] 胡晓晟[1] 王利宏[1] 连苗军[1] 

机构地区：[1]浙江大学医学院附属第一医院心内科,杭州310003

出　　处：《浙江医学》2005年第7期493-495,共3页Zhejiang Medical Journal

摘　　要：目的观察极低剂量培哚普利/吲达帕胺复合制剂(商品名:百普乐)治疗原发性高血压患者的降压疗效及安全性。方法门诊原发性高血压患者经2周的安慰剂选择期后,进入12周随机、双盲平行组治疗期,采用随机、双盲、吲达帕胺缓释剂(商品名:纳催离)作对照。结果治疗后百普乐组患者血压由治疗前的(141.2±9.0)?(97.3±3.0)mmHg下降至(125.9±7.2)?(83.0±5.2)mmHg,有效率91.3%;纳催离组血压由治疗前的(144.1±11.9)?(99.6±4.4)mmHg下降至(125.5±11.3)?(81.9±7.5)mmHg,有效率89.9%。两组经治疗后血压均有效下降(均P<0.001)。百普乐组患者咳嗽发生率20.8%,因不能耐受而退出1例(4.2%);纳催离组低钾血症发生率为25.0%。结论百普乐治疗原发性高血压安全有效。Objective To investigate the efficacy and safety of the combination of Perindopril and Indapamide Biprel in treatment of essential hypertensive patients. Method A randomized double-blind placebo-controlled clinical trial was conducted. Total of 56 outpatients with essential hypertension were recruited in the study after 2-week placebo selection period 48 patients entered in 12-week trial with 2 parallel arms in treatment arm 22 patients received Biprel Perindopril 2mg Indapamide 0.625mg and in control arm 22 patients received Indapamide 1.5mg SRNatrilix. The changes in sitting blood pressure from baseline and the laboratory abnormalities hypokalemia ECG changes and adverse events were compared in two arms. Result Biprel reduced sitting blood pressure from (141.2±9.0) (97.3±3.0)mmHg to (125.9±7.2) (83.0±5.2)mmHg with a response rate of 91.3% Natrilix reduced sitting blood pressure from (144.1±11.9) (99.6±4.4)mmHg to (125.5±11.3) (81.9±7.5)mmHg with a response rate of 89.9% both groups P<0.001. Cough was presented in 20.8% of patients in Biprel group but only one patient withdrew 4.2% the incidence of hypokalemia was 25% in the Natrilix group and none in Biprel group. Conclusions Biprel was effective and well tolerated and offers a promising approach to the treatment of essential hypertension. 

关 键 词：培哚普利 吲达帕胺 原发性高血压 降压作用 安全性 血管紧张素 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]